# Pulmonary Vasodilators

|Property|Nitric Oxide|Iloprost|Sildenafil
|--|--|
|**Class**|Inorganic gas|Synthetic eicosanoid with prostacyclin activity
|**Uses**|ARDS, RVF, PHTN|PHTN|PHTN, erectile dysfunction
|**Presentation**|Aluminium cylinders with 100/800ppm NO/N<sub>2</sub>|Synthetic analogue of epoprostenol||
|**Route of Administration**|Inhaled|Inhaled|PO|
|**Dosing**|1-40ppm, via inspiratory limb of ventilator||20mg TDS
|**Absorption**|||40% PO bioavailability
|**Distribution**|Avidly bound to Hb||95% protein bound, V<sub>D</sub> of 100L
|**Metabolism**|Metabolised to methaemoglobin and nitrite prior to reaching systemic circulation - t<sub>1/2</sub> of < 5s||Hepatic by CYP450
|**Elimination**|||Faecal
|**Mechanism of Action**|Stimulates cGMP which reduces intracellular Ca<sup>2+</sup>|Stimulates cAMP which reduces intracellular Ca<sup>2+</sup> and smooth muscle growth|Inhibits cGMP
|**Resp**|Inhibits HPV, improves V/Q matching|||
|**CVS**|↓ vascular resistance, ↓ PVR in ventilated alveoli and improving V/Q matching. ↑ Capillary permeability.|↓ BP with compensatory ↑ HR|↓ PVR
|**CNS**|↑ CBF|||
|**Haeme**|Inhibits platelet aggregation. MetHb|Inhibits platelet aggregation||
|**Other**|Rebound pulmonary HTN on abrupt cessation||||

---
##References
1. Peck TE, Hill SA. Pharmacology for Anaesthesia and Intensive Care. 4th Ed. Cambridge University Press. 2014.  
2. Smith S, Scarth E, Sasada M. Drugs in Anaesthesia and Intensive Care. 4th Ed. Oxford University Press. 2011.
